Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and chemotherapy in unresectable stage III NSCLC
NCT05611879Phase 2Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Resectability rate. Started Mar 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05611879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611879.